The aim of this study was to analyze the impact of BCR-ABL+ ALL on the heart, as well as the effect of an anti-cancer pharmacotherapy consisting of DAS, DEX and VEN in terms of function and molecular mechanisms. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.